How much is the regular price of Osimertinib (Tagressa)?

Osimertinib (Tagrisso) is a targeted therapy drug mainly used to treat EGFR (epidermal growth factor receptor) mutant lung cancer in non-small cell lung cancer (NSCLC). It belongs to the third generation of EGFR tyrosine kinase inhibitors and has higher selectivity and potency and less drug resistance than the first and second generation EGFR inhibitors.

Osimertinib (Tagressa) has now been launched in the domestic market and has been included in the reimbursement scope of medical insurance. Patients can easily buy it at the pharmacies of major hospitals in China, and the price is about four to five thousand yuan. However, please note that drug prices and medical insurance reimbursement details may vary by region. It is recommended to directly consult the nearest hospital pharmacy to obtain the most accurate information.

In addition, if you are looking for a more affordable option, you can consider foreignosimertinib (Tagressa) generic drugs, such as the versions produced in Laos and Bangladesh, which are affordable and only cost a few hundred yuan, which significantly reduces the cost compared to the domestic version. It is worth mentioning that the ingredients of these generic drugs are almost the same as those of domestic original drugs.

Osimertinib (Tagressa) blocks the abnormal activation of the EGFR signaling pathway by inhibiting the activity of EGFR, thereby inhibiting the growth and spread of tumor cells. It is particularly suitable for EGFR T790Mmutation-positive late-stage NSCLC patients, which is a common EGFR resistance mutation. In addition, Osimertinib (Tagressa) is also approved for first-line treatment of patients with advanced NSCLC who have EGFRsensitivity mutations.

Althoughosimertinib (Tagrisso)has shown significant efficacy and low side effects in the treatment ofNSCLC, the patient's condition and drug tolerance still need to be closely monitored during the treatment process in order to adjust the treatment plan in a timely manner. At the same time, due to possible drug resistance and relapse, patients also need regular follow-up and evaluation during treatment with Osimertinib (Tagressa) to ensure sustained and effective treatment effects.